CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving the delivery of RNA and gene therapies for lung cancer by using genetically modified extracellular vesicles and advanced aerosol technology. It aims to overcome barriers such as mucus in the lungs to enhance treatment effectiveness and patient outcomes.
Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy.
However, LC is a complex heterogeneous disease and survival rates remain poor. RNA (mRNA, microRNA, other non-coding RNAs and nucleic acid based modulators of same) and gene therapies (DNA or gene editing) for delivering nucleic acid-based therapeutics have curative potential for a host of indications previously untreatable.
They have yet to enter the mainstream, due to safety concer…
MYRIAD CONSULTING LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Ireland, Galway
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Ireland, Dublin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Paris
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Heidelberg
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
